JAMA, COVID-19 and Excess All-Cause Mortality in the US and 18 Comparison Countries

November 29, 2020 James Fetzerblog

Research Letter

[Editor’s note: We now have at least three sources of scientific studies that report there is no difference in the mortality rate with and without COVID-19, which means that its presence or absence appears to be statistically irrelevant (makes no difference), which in turn strongly suggests that its presence or absence is not causally relevant (that it is not causing people to die). These findings are consistent with and confirm my previous research on The Coronavirus Phenomenon: Medical Emergency or Political Pandemic? In which case, we have (what may well be) the greatest hoax ever played upon the world since the Moon Landing Hoax: How we Know we Didn’t Go, which, however, was not politically significant for the economic, physical and psychological future of the species.] 

October 12, 2020

Alyssa Bilinski, MSc¹; Ezekiel J. Emanuel, MD, PhD²

Author Affiliations Article Information

JAMA. 2020;324(20):2100-2102. doi:10.1001/jama.2020.20717

COVID-19 Resource Center

The patterns found for COVID-19–specific deaths were similar for excess all-cause mortality

The US has experienced more deaths from coronavirus disease 2019 (COVID-19) than any other country and has one of the highest cumulative per capita death rates.^1,2 An unanswered question is to what extent high US mortality was driven by the early surge of cases prior to improvements in prevention and patient management vs a poor longer-term response.³ We compared US COVID-19 deaths and excess all-cause mortality in 2020 (vs 2015-2019) to that of 18 countries with diverse COVID-19 responses.

Methods

We compared the US with Organisation for Economic Co-operation and Development countries with populations exceeding 5 million and greater than $25 000 per capita gross domestic product. For each country, we calculated the COVID-19 per capita mortality rate and grouped countries by mortality: (1) low (COVID-19 deaths, <5/100 000), (2) moderate (5-25/100 000), and (3) high (>25/100 000).¹ We used Poisson regression for comparisons across countries.

We calculated the difference in COVID-19 deaths between each country and the US through September 19, 2020 (week 38) under 3 scenarios: if the US had a comparable per capita COVID-19 mortality rate to each country from the start of the pandemic (February 13) or if the US mortality rate became comparable to other countries beginning May 10 or June 7, to allow lag time for policy interventions.³ (See the Supplement for formulas.)

The Johns Hopkins study showing no difference even in the elderly mysteriously disappeared.

Results

On September 19, 2020, the US reported a total of 198 589 COVID-19 deaths (60.3/100 000), higher than countries with low and moderate COVID-19 mortality but comparable with high-mortality countries (Table 1). For instance, Australia (low mortality) had 3.3 deaths per 100 000 and Canada (moderate mortality) had 24.6 per 100 000. Conversely, Italy had 59.1 COVID-19 deaths per 100 000; Belgium had 86.8 per 100 000. If the US death rates were comparable to Australia, the US would have had 187 661 fewer COVID-19 deaths (94% of reported deaths), and if comparable with Canada, 117 622 fewer deaths (59%).

While the US had a lower COVID-19 mortality rate than high-mortality countries during the early spring, after May 10, all 6 high-mortality countries had fewer deaths per 100 000 than the US. For instance, between May 10 and September 19, 2020, Italy’s death rate was 9.1/100 000 while the US’s rate was 36.9/100 000. If the US had comparable death rates with most high-mortality countries beginning May 10, it would have had 44 210 to 104 177 fewer deaths (22%-52%) (Table 1). If the US had comparable death rates beginning June 7, it would have had 28% to 43% fewer reported deaths (as a percentage overall).

In the 14 countries with all-cause mortality data, the patterns found for COVID-19–specific deaths were similar for excess all-cause mortality (Table 2). In countries with moderate COVID-19 mortality, excess all-cause mortality remained negligible throughout the pandemic. In countries with high COVID-19 mortality, excess all-cause mortality reached as high as 102.1/100 000 in Spain, while in the US it was 71.6/100 000. However, since May 10 and June 7, excess all-cause mortality was higher in the US than in all high-mortality countries (Table 2).

Reported increase in CV deaths almost equals exactly the decrease from all other causes.

Discussion

Compared with other countries, the US experienced high COVID-19–associated mortality and excess all-cause mortality into September 2020. After the first peak in early spring, US death rates from COVID-19 and from all causes remained higher than even countries with high COVID-19 mortality. This may have been a result of several factors, including weak public health infrastructure and a decentralized, inconsistent US response to the pandemic.^4,5

Limitations of this analysis include differences in mortality risk: the US population is younger but has more comorbidities compared with the other countries.⁶ In addition, since late August death rates have increased in several countries, and how mortality will compare with the US throughout fall remains unknown.

Article Information

Corresponding Author: Ezekiel J. Emanuel, MD, PhD, Perelman School of Medicine, University of Pennsylvania, Medical Ethics and Health Policy, 423 Guardian Dr, Blockley Hall, Ste 1412, Philadelphia, PA 19104 (MEHPchair@upenn.edu).

Accepted for Publication: October 2, 2020.

Published Online: October 12, 2020. doi:10.1001/jama.2020.20717

Author Contributions: Ms Bilinski had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design; acquisition, analysis, or interpretation of data; and drafting of the manuscript: Both authors.

Critical revision of the manuscript for important intellectual content: Emanuel.

Statistical analysis: Bilinski.

Obtained funding: Emanuel.

Administrative, technical, or material support: Emanuel.

Supervision: Emanuel.

Conflict of Interest Disclosures: Dr Emanuel reported receiving personal fees and nonfinancial support from Blue Cross Blue Shield Minnesota, Bergen University, United Health Group, Futures Without Violence, Children’s Hospital of Philadelphia, Washington State Hospital Association, the Association of Academic Health Centers, Blue Cross Blue Shield of Massachusetts, Lumeris, Roivant Sciences, Medical Specialties Distributors, Vizient University Health System Consortium, the Center for Neurodegenerative Disease Research, Genentech Oncology, the Council of Insurance Agents and Brokers, America’s Health Insurance Plans, the Montefiore Physician Leadership Academy, Medical Home Network, the Healthcare Financial Management Association, Ecumenical Center–UT Health, the American Academy of Optometry, the Associação Nacional de Hospitais Privados, the National Alliance of Healthcare Purchaser Coalitions, Optum Labs, the Massachusetts Association of Health Plans, the District of Columbia Hospital Association, Washington University, Optum, Brown University, McKay Lab, the American Society for Surgery of the Hand, the Association of American Medical Colleges, America’s Essential Hospitals, Johns Hopkins University, the National Resident Matching Program, Shore Memorial Health System, Tulane University, Oregon Health and Science University, Blue Cross Blue Shield, and the Center for Global Development, as well as nonfinancial support from the Delaware Healthcare Spending Benchmark Summit, Geisinger Health System, RAND Corporation, Goldman Sachs, The Atlantic, Village MD, and Oncology Analytics. Dr Emanuel is also a venture partner at Oak HC/FT, and a partner at Embedded Healthcare LLC and COVID-19 Recovery Consulting. Ms Bilinski reported no disclosures.

Funding/Support: This research was partially funded by the Colton Foundation.

Role of the Funder/Sponsor: The Colton Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We thank David Cutler, PhD, of the Harvard University Department of Economics, for helpful feedback, for which he received no compensation.

Additional Information: Data and code are publicly available on GitHub.

 

References

1.

COVID-19 data. European Centre for Disease Prevention and Control. Accessed September 25, 2020. https://www.ecdc.europa.eu/en/covid-19/data

2.

Viglione  G.  How many people has the coronavirus killed?   Nature. 2020;585(7823):22-24. doi:10.1038/d41586-020-02497-wPubMedGoogle ScholarCrossref

3.

Lyu  W, Wehby  GL.  Shelter-in-place orders reduced COVID-19 Mortality and reduced the rate of growth in hospitalizations: study examine effects of shelter-in-places orders on daily growth rates of COVID-19 deaths and hospitalizations using event study models.   Health Aff (Millwood). 2020;39(9):1615-1623. doi:10.1377/hlthaff.2020.00719PubMedGoogle ScholarCrossref

4.

Verity  R, Okell  LC, Dorigatti  I,  et al.  Estimates of the severity of coronavirus disease 2019: a model-based analysis.   Lancet Infect Dis. 2020;20(6):669-677. doi:10.1016/S1473-3099(20)30243-7PubMedGoogle ScholarCrossref

5.

Maani  N, Galea  S.  COVID-19 and underinvestment in the public health infrastructure of the United States.   Milbank Q. 2020;98(2):250-259. doi:10.1111/1468-0009.12463PubMedGoogle ScholarCrossref

6.

Chaudhry  R, Dranitsaris  G, Mubashir  T, Bartoszko  J, Riazi  S.  A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes.   EClinicalMedicine. 2020;25:100464. doi:10.1016/j.eclinm.2020.100464PubMedGoogle Scholar

Please follow and like us: